This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Huang J , Zhang L , Greshock J , Colligon TA , Wang Y , Ward R , Katsaros D , Lassus H , Butzow R , Godwin AK , Testa JR , Nathanson KL , Gimotty PA , Coukos G , Weber BL , Degenhardt Y
Frequent Genetic Abnormalities of the PI3K/AKT Pathway in Primary Ovarian Cancer Predict Patient Outcome
Genes Chromosomes & Cancer. 2011 Aug;50(8) :606-618
AbstractIdentification and characterization of underlying genetic aberrations could facilitate diagnosis and treatment of ovarian cancer. Copy number analysis using array Comparative Genomic Hybridization (aCGH) on 93 primary ovarian tumors identified PI3K/AKT pathway as the most frequently altered cancer related pathway. Furthermore, survival analyses to correlate gene copy number and mutation data with patient outcome showed that copy number gains of PIK3CA, PIK3CB, and PIK3R4 in these tumors were associated with decreased survival. To confirm these findings at the protein level, immunohistochemistry (IHC) for PIK3CA product p110 alpha and p-Akt was performed on tissue microarrays from 522 independent serous ovarian cancers. Overexpression of either of these two proteins was found to be associated with decreased survival. Multivariant analysis from these samples further showed that overexpression of p-AKT and/or p110 alpha is an independent prognostic factor for these tumors. siRNAs targeting altered PI3K/AKT pathway genes inhibited proliferation and induced apoptosis in ovarian cancer cell lines. In addition, the effect of the siRNAs in different cell lines seemed to correlate with the particular genetic alterations that the cell line carries. These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer. They also suggest identifying the specific component in the PI3K pathway that is genetically altered has the potential to help select the most effective therapy. Both mutation as well as copy number changes can be used as predictive markers for this purpose. (C) 2011 Wiley-Liss, Inc.
NotesHuang, Jia Zhang, Lin Greshock, Joel Colligon, Theresa A. Wang, Yan Ward, Renee Katsaros, Dionyssios Lassus, Heini Butzow, Ralf Godwin, Andrew K. Testa, Joseph R. Nathanson, Katherine L. Gimotty, Phyllis A. Coukos, George Weber, Barbara L. Degenhardt, Yan Wiley-blackwell Malden 777bp